N/A
N=1,915
Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
Diabetic Neuropathic Pain
Bottom Line
View on ClinicalTrials.gov: NCT02783469 ↗Enrolled (actual)
1,915
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcome: Primary: Neuropathic Pain — 482; 461; 560 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Identification of genetic causes of diabetic neuropathic pain (Genetic)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Dundee
- Primary completion
- May 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Neuropathic Pain |
482; 461; 560 | — |
Summary
In 1997, the global prevalence of diabetes was estimated to be 125 million and this has risen to around 400 million in 2015. In addition diabetes has a number of complications including heart disease, blindness, kidney failure and amputation. This represents a significant burden on healthcare services. Type 2 diabetes (T2D) is caused by a combination of genetic and environmental factors. The aim of GoDARTS is to recruit participants with T2D to a registry to provide a platform with which to investigate the genetics of T2D, its complications and response to treatment. This study will investigate the genetic basis of diabetic neuropathic pain.
Eligibility Criteria
Inclusion Criteria
- Previous participation with GoDARTS
- Existing consent to be recontacted
- Identified as being currently alive
- Currently has a postal address
- age > 18 years
- Neuropathic
Exclusion Criteria
- Unable to give consent
- No current postcode
- Identified as having died
Data sourced from ClinicalTrials.gov (NCT02783469). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.